Sean A. Power - 20 Jul 2022 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Role
Chief Financial Officer
Signature
/s/ Sean A. Power
Issuer symbol
TGTX
Transactions as of
20 Jul 2022
Transactions value $
$0
Form type
4
Filing time
22 Jul 2022, 16:33:48 UTC
Previous filing
07 Jan 2022
Next filing
14 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TGTX Common Stock Award $0 +75,000 +13% $0 643,483 20 Jul 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TGTX Employee Stock Option (right to buy) Award $0 +200,000 $0 200,000 20 Jul 2022 Common Stock, par value $0.001 200,000 $7 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab.
F2 Includes shares of restricted Common Stock, which vest over various time periods.
F3 Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis.